Specific Overexpression of Cyclin E·CDK2 in Early Preinvasive and Primary Breast Tumors in Female ACI Rats Induced by Estrogen
- 192 Downloads
Overexpressed Aurora A, amplified centrosomes, and aneuploidy are salient features of estrogen-induced mammary preinvasive lesions and tumors in female August–Copenhagen Irish (ACI) rats. Intimately involved in these events are cyclins and their associated cyclin-dependent kinase (CDK) partners. Cyclin E1·CDK2 overexpression plays an important dual role in late G1/S phase of the cell cycle in cancer cells. It increases DNA replication providing growth advantage to cancer cells and facilitates aberrant centrosome duplication, generating chromosomal instability and aneuploidy leading to tumor development. Presented herein, a 24.0- and 45.0-fold elevation in cyclin E1 and CDK2 was found in 17β-estradiol (E2)-induced ACI rat mammary tumors (MTs), respectively. Cyclin E·CDK2 positive staining was confined to the large round cells found within focal dysplasias, ductal carcinomas in situ, and invasive MTs. Co-immunoprecipitation and in vitro kinase activity of these tumors revealed that these cell cycle entities are functional. When mammary tissue derived from untreated normal, E2-induced hyperplasia and primary tumors were normalized to cyclin E1 levels, low molecular weight (LMW) cyclin E1 forms (33- and 45-kDa) were detected in all of these tissue groups. Moreover, increasing concentrations of protease inhibitor in tissue lysates resulted in a marked reduction of LMW forms, indicating that the presence of cyclin E1 LMW forms can be markedly reduced. Significant increases in cyclin E1 mRNA (2.1-fold) were detected in primary ACI rat E2-induced breast tumors, and quantitative real-time polymerase chain reaction revealed a 20% amplification of the cyclin E1 gene (CCNE1). Collectively, these results support the involvement of cyclin E1·CDK2 in centrosome overduplication during each stage of E2-induced mammary tumorigenesis.
KeywordsCyclin E1·CDK2 Estrogen ACI rat Breast cancer
Cyclin E1 gene
Ductal carcinoma in situ
Estrogen receptor α
Low molecular weight
The authors acknowledge the expert clerical assistance of Ms. Lauren Overton from the University of Kansas Medical Center, Department of Pharmacology.
- 1.The American Cancer Society (2008) Cancer facts & figures 2008. The American Cancer Society, New YorkGoogle Scholar
- 2.Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A et al (2007) Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 16:439–443CrossRefPubMedGoogle Scholar
- 3.Surveillance, Epidemiology, and End Results (SEER) Oncogene. 2008 Feb 21; 27(9):1253-1262. Program (www.seercancer.gov) SEER*Stat, Database: Incidence- SEER17 Reqs Limited-Use, Nov. 2006 Sub (2000-2004) Linked to County, Attributes- Total US 1969-2004 Counties, National Cancer Institute, DCCPS, Surveillance, Research Program, Cancer Statistics Branch, released April 2007. Based on the November 2006 submission
- 4.Alberts SR, Ingle JN, Roche PR, Cha SS, Wold LE, Farr GH Jr, Krook JE, Wieand HS (1996) Comparison of estrogen receptor determinations by a biochemical ligand-binding assay and immunohistochemical staining with monoclonal antibody ER1D5 in females with lymph node positive breast carcinoma entered on two prospective clinical trials. Cancer 78:764–772CrossRefPubMedGoogle Scholar
- 27.Li JJ, Li SA (2007) Deciphering the conundrum of estrogen-driven breast cancer: Aurora kinase deregulation. In: Melmed SRH, Chanson P, Christen Y (eds) Hormonal control of cell cycle. Springer, Heidelberg, pp 49–62Google Scholar
- 35.Wang X-J, Greenhalgh DA, Jiang A, He D, Zhong L, Brinkley BR, Toop DR (1998) Analysis of centrosome abnormalities and angiogenesis in epidermal-target p53172H mutant and p53-knockout mice after chemical carcinogenesis: evidence for a gain of function. Mol Carcinogenesis 23:185–192CrossRefGoogle Scholar